Are there any special considerations when evaluating patients with non-malignant hematologic or immunodeficiency disorders for allogeneic transplant?  

Are there major differences in standard conditioning and/or GVHD prophylaxis regimens utilized?

Does the non-relapse mortality different significantly versus patients undergoing allogeneic HSCT for malignant diseases?



Answer from: Medical Oncologist at Academic Institution

Answer from: at Academic Institution
Comments
at Ann & Robert H. Lurie Children’s Hospital of Chicago
Thank you Dr. @Biljana Horn for your thoughtful re...
Sign in or Register to read more

Answer from: at Academic Institution
Comments
at Ann & Robert H. Lurie Children’s Hospital of Chicago
Thank you Dr. @Jignesh Dalal for your response! Is...
at CWRU School of Medicine
At least for 1 month if not two.
Sign in or Register to read more